According to Reuters recent report, Roche's spinal muscular atrophy (SMA) drug Risdiplam hit another clinical trial target, the Swiss drugmaker said on Thursday, which analysts said bolsters its prospects of reaching $2 billion in annual sales.

Roche's study of 41 patients measured whether infants could sit independently for at least 5 seconds after 12 months of treatment. Roche, whose Risdiplam aims to join Biogen's BIIB.O Spinraza and Novartis's NOVN.S gene therapy Zolgensma as approved SMA treatments said no safety problems emerged that led patients to halt treatment.

U.S. regulators are due to decide by May 24.